This article was originally published in The Gray Sheet
Executive SummaryDiagnostics firms bioMerieux, Gen-Probe and Quidel recently joined AdvaMed's newly formed in-vitro-diagnostics-focused AdvaMed Dx division (1"The Gray Sheet" Dec. 21, 2009). Each of the companies had been in AdavMed at one time, but had let their memberships lapse
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.